Treatment of bacterial meningitis

New England Journal of Medicine

Volumn 336, Issue 10, 1997, Pages 708-716

  Quagliarello, Vincent J ^a   Scheld, W Michael ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; DEXAMETHASONE; GENTAMICIN; PENICILLIN G; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BACTERIUM DETECTION; CEREBROSPINAL FLUID ANALYSIS; CORTICOSTEROID THERAPY; DRUG POTENTIATION; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MENINGITIS, BACTERIAL; PENICILLINS;

EID: 0031048865     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199703063361007     Document Type: Review

References (96)

1. Bell WE, McCormick WF. Neurologic infections in children. 2nd ed. Vol. 12 of Major problems in clinical pediatrics. Philadelphia: W.B. Saunders, 1981:77-80.
2. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913;17:553-76.
3. Scheld WM, Mandell GL. Sulfonamides and meningitis. JAMA 1984; 251:791-4.
4. Schwentker FF, Gelman S, Long PH. The treatment of meningococcic meningitis with sulfanilamide. JAMA 1937;108:1407-8.
5. Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993;122:15-21.
6. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med 1993;328:21-8.
7. Quagliarello VJ, Scheld WM. New perspectives on bacterial meningitis. Clin Infect Dis 1993;17:603-10.
8. Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV, Bacterial Meningitis Study Group. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J Infect Dis 1990;162: 1316-23.
9. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
10. Broome CV, Wenger JD, Schuchat A, Plikaytis BD, Deaver K. Changing epidemiology of bacterial meningitis in the United States. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996. Washington, D.C.: American Society for Microbiology, 1996:311. abstract.
11. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967;2: 264-5.
12. Naraqi S, Kirkpatrick GP, Kabins S. Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G. J Pediatr 1974;85:671-3.
13. Coffey TJ, Daniels M, McDougal LK, Dowson CG, Tenover FC, Spratt BG. Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1995;39:1306-13.
14. Fenoll A, Martin Bourgon C, Munoz R, Vicioso D, Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991; 13:56-60.
15. Marton, A, Gulyas M, Munoz R, Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis 1991;163:542-8.
16. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992;146:920-3.
17. Yoshida R, Kaku M, Kohno S, et al. Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrob Agents Chemother 1995;39:1196-8.
18. Jones RN, Kehrberg E, Erwin ME, Sader H. Epidemiologic studies of emerging antimicrobial resistance in USA hospitals: report from a forty medical center surveillance of parenteral drug susceptibility. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 4-7, 1994. Washington, D.C.: American Society for Microbiology, 1994:87. abstract.
19. Hoffmann J, Cetron MS, Farley MM, et al. The prevalence: of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333: 481-6.
20. Zwahlen A, Nydegger UE, Vaudaux P, Lambert P-H, Waldvogel FA. Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis. J Infect Dis 1982;145:635-46.
21. Feldman WE. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr 1976;88:549-52.
22. Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979: frequent causes of meningitis in adults. Am J Med 1981;71:199-209.
23. Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983;71:411-9.
24. Sande MA. Factors influencing the penetration and activity of antibiotics in experimental meningitis. J Infect 1981;3:Suppl:33-8.
25. Tauber MG, Sande MA. General principles of therapy of pyogenic meningitis. Infect Dis Clin North Am 1990;4:661-76.
26. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967;34:207-17.
27. Quagliarello VJ, Long WJ, Scheld WM. Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat: temporal sequence and role of encapsulation. J Clin Invest 1986;77:1084-95.
28. Quagliarello VJ, Ma A, Stukenbrok H, Palade GE. Ultrastructural localization of albumin transport across the cerebral microvasculature during experimental meningitis in the rat. J Exp Med 1991;174:657-72.
29. Tauber MG, Doroshow CA, Hackbarth CJ, Rusnak MG, Drake TA, Sande MA. Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis 1984;149:568-74.
30. Strausbaugh LJ, Sande MA. Factors influencing the therapy of experimental Proteus mirabilis meningitis in rabbits. J Infect Dis 1978;137:251-60.
31. Small PM, Tauber MG, Hackbarth CJ, Sande MA. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect Immun 1986;52:484-7.
32. Ramilo O, Saez-Llorens X, Mertsola J, et al. Tumor necrosis factor α/cachectin and interleukin 1 β initiate meningeal inflammation. J Exp Med 1990;172:497-507.
33. Quagliarello VJ, Wispelwey B, Long WJ Jr, Scheld WM. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat: characterization and comparison with tumor necrosis factor. J Clin Invest 1991;87:1360-6.
34. Mustafa MM, Ramilo O, Mertsola J, et al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type b meningitis. J Infect Dis 1989;160:818-25.
35. Friedland IR, Jafari H, Ehrett S, et al. Comparison of endotoxin release by different antimicrobial agents and the effect on inflammation in experimental Escherichia coli meningitis. J Infect Dis 1993;168:657-62. [Erratum, J Infect Dis 1993;168:1342.]
36. Feigin RD, Kaplan SL. Commentary. Pediatr Infect Dis J 1992;11: 698-700.
37. Radetsky M. Duration of symptoms and outcome in bacterial meningitis: an analysis of causation and the implications of a delay in diagnosis. Pediatr Infect Dis J 1992;11:694-8.
38. Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990;322:141-7.
39. Talan DA, Zibulewsky J. Relationship of clinical presentation to time to antibiotics for the emergency department management of suspected bacterial meningitis. Ann Emerg Med 1993;22:1733-8.
40. Coant PN, Kornberg AE, Duffy LC, Dryja DM, Hassan SM. Blood culture results as determinants in the organism identification of bacterial meningitis. Pediatr Emerg Care 1992;8:200-5.
41. Tauber MG, Khayam-Bashi H, Sande MA. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumoccocal meningitis. J Infect Dis 1985;151:528-34.
42. Syrogiannopoulos GA, Olsen KD, Reisch JS, McCracken GH Jr. Dexamethasone in the treatment of Haemophilus influenzae type b meningitis. J Infect Dis 1987;155:213-9. [Erratum, J Infect Dis 1987;155: 1359.]
43. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 1992;327:864-72.
44. Wald ER, Kaplan SI, Mason EO Jr, et al. Dexamethasone therapy for children with bacterial meningitis. Pediatrics 1995;95:21-8.
45. Kanra GY, Ozen H, Secmeer G, Ceyhan M, Ecevit Z, Belgin E. Beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J 1995;14:490-4.
46. Girgis NI, Farid Z, Mikhail IA, Farrag I, Sultan Y, Kilpatrick ME. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J 1989;8:848-51.
47. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials. N Engl J Med 1988;319:964-71.
48. Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991;324:1525-31.
49. Schaad UB, Lips U, Gnehm HE, Blumberg A, Heinzer I, Wedgwood J. Dexamethasone therapy for bacterial meningitis in children. Lancet 1993;342:457-61.
50. Syrogiannopoulos GA, Lourida AN, Theodoridou MC, et al. Dexamethasone therapy for bacterial meningitis in children: 2-versus 4-day regimen. J Infect Dis 1994;169:853-8.
51. Leggiadro RJ. Penicillin- and cephalosporin-resistant Streptococcus pneumoniae: an emerging microbial threat. Pediatrics 1994;93:500-3.
52. Viladrich PF, Gudiol F, Linares J, Rufi G, Ariza J, Pallares R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med 1988;84:839-46.
53. Bradley JS, Connor JD. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J 1991;10:871-3.
54. Sloas MM, Barrett FF, Chesney PJ, et al. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1992;11:662-6.
55. Friedland IR, Shelton S, Paris M, et al. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1993;12:196-200.
56. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331: 377-82.
57. Performance standards for antimicrobial susceptibility testing: for bacteria that grow aerobically: approved standard M7-A3 (M100-S6). Vol. 15. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1995.
58. Tan TQ, Schutze GE, Mason EO Jr, Kaplan SL. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994;38:918-23.
59. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992;339:405-8.
60. Friedland IR, Shelton S, McCracken GH Jr. Chloramphenicol in penicillin-resistant pneumococcal meningitis. Lancet 1993;342:240-1.
61. Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991;35:2467-72.
62. Friedland IR, Paris MM, Ehrett S, Hickey S, Olsen K, McCracken GH Jr. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993;37:1630-6.
63. Paris MM, Hickey SM, Uscher MI, Shelton S, Olsen KD, McCracken GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994;38:1320-4.
64. Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995;39:1988-92.
65. Dillon JR, Pauze M, Yeung K-H. Spread of penicillinase-producing and transfer plasmids from the gonococcus to Neisseria meningitidis. Lancet 1983;1:779-81.
66. Van Esso D, Fontanals D, Uriz S, et al. Neisseria meningitidis strains with decreased susceptibility to penicillin. Pediatr Infect Dis J 1987;6:438-9.
67. Saez-Nieto JA, Lujan R, Berron S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1992;14:394-402.
68. Woods CR, Smith AL, Wasilauskas BL, Campos J, Givner LB. Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. J Infect Dis 1994;170:453-6.
69. Sutcliffe EM, Jones DM, el-Sheikh S, Percival A. Penicillin-insensitive meningococci in the UK. Lancet 1988;1:657-8.
70. Jones DM, Sutcliffe EM. Meningococci with reduced susceptibility to penicillin. Lancet 1990;335:863-4.
71. Skogberg K, Syrjanen J, Jahkola M, et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis 1992;14:815-21.
72. Scheld WM, Fletcher DD, Funk FN, Sande MA. Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes. J Infect Dis 1979;140:287-94.
73. Tunkel AR, Wispelwey B, Scheld WM. Bacterial meningitis: recent advances in pathophysiology and treatment. Ann Intern Med 1990;112:610-23.
74. Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxasole for bacterial meningitis. Ann Intern Med 1984;100:881-90.
75. Dryden MS, Jones NF, Phillips I. Vancomycin therapy failure in Listeria monocytogenes peritonitis in a patient on continuous ambulatory peritoneal dialysis. J Infect Dis 1991;164:1239-40.
76. Nairn K, Shepherd GL, Edwards JR. Efficacy of meropenem in experimental meningitis. J Antimicrob Chemother 1995;36:Suppl A:73-84.
77. Deveikis A, Schauf V, Mizen M, Riff L. Antimicrobial therapy of experimental group B streptococcal infection in mice. Antimicrob Agents Chemother 1977;11:817-20.
78. Dunne DW, Quagliarello VJ. Group B streptococcal meningitis in adults. Medicine (Baltimore) 1993;72:1-10.
79. McCracken GH Jr, Mize SG. A controlled study of intrathccal antibiotic therapy in gram-negative enteric meningitis of infancy: report of the Neonatal Meningitis Cooperative Study Group. J Pediatr 1976;89:66-72.
80. McCracken GH Jr, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy: report of the Second Neonatal Meningitis Cooperative Study Group. Lancet 1980;1:787-91.
81. Wright PF, Kaiser AB, Bowman CM, McKee KT Jr, Trujillo H, McGee ZA. The pharmacokinetics and efficacy of an aminoglycoside administered into the cerebral ventricles in neonates: implications for further evaluation of this route of therapy in meningitis. J Infect Dis 1981;143:141-7.
82. Landesman SH, Corrado ML, Shah PM, Armengaud M, Barza M, Cherubin CE. Past and current roles for cephalosporin antibiotics in treatment of meningitis: emphasis on use in gram-negative bacillary meningitis. Am J Med 1981;71:693-703.
83. Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604-12.
84. Rodriguez WJ, Khan WN, Cocchetto DM, Feris J, Puig JR, Akram S. Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy. Pediatr Infect Dis J 1990;9:83-7.
85. Lentnek AL, Williams RR. Aztreonam in the treatment of gram-negative bacterial meningitis. Rev Infect Dis 1991;13:Suppl 7:S586-S590.
86. Wolff MA, Young CL, Ramphal R. Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. Clin Infect Dis 1993;16:772-7.
87. Green SDR, Ilunga F, Cheesbrough JS, Tillotson GS, Hichens M, Felmingham D. The treatment of neonatal meningitis due to Gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect 1993;26:253-6.
88. Donnelly JP, Horrevorts AM, Sauerwein RW, De Pauw BE. High-dose meropenem in meningitis due to Pseudomonas aeruginosa. Lancet 1992; 339:1117.
89. Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-5.
90. Lin T-Y, Chrane DF, Nelson JD, McCracken GH Jr. Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis. JAMA 1985;253:3559-63.
91. Martin E, Hohl P, Guggi T, Kayser FH, Fernex M. Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study. I. Clinical results. Infection 1990;18: 70-7.
92. O'Neill P. How long to treat bacterial meningitis. Lancet 1993;341: 530. [Erratum, Lancet 1993;341:642.]
93. Wali SS, Macfarlane JT, Weir WR, et al. Single injection treatment of meningococcal meningitis. 2. Long-acting chloramphenicol. Trans R Soc Trop Med Hyg 1979;73:698-702.
94. Elmore JG, Horwitz RI, Quagliarello VJ. Acute meningitis with a negative Gram's stain: clinical and management outcomes in 171 episodes. Am J Med 1996;100:78-84.
95. Jones DM. Current and future trends in immunization against meningitis. J Antimicrob Chemother 1993;31:Suppl B:93-9.
96. PHLS Communicable Disease Surveillance Centre. Quarterly communicable disease review October to December 1994. J Public Health Med 1995;17:230-7.